iFabric Announces Publication of Groundbreaking Clinical Trial Proving the Infection Control Ability of Protx2(R) And Ecopel(TM) Treated Scrubs

Stock Information for iFabric Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iFabric Corp.

iFabric Corp Delivers Record Q3 2025 Revenue of $9.0 Million, up 111% Year-Over-Year
iFabric Launching Verzus All Apparel Brand at Major Canadian Wholesale Club Retailer
iFabric Corp Secures New $2.5 Million Trade Finance Facility
iFabric Launches Scrubs Program at Major US Retailer
iFabric & Doctor's Choice(R) Sign Next-Generation Scrubs & Medical Apparel Agreement
iFabric Announces Renewal of License Agreement with TUMI to Continue Integration of PROTX2(R) Technology
iFabric Corp. Announces Expansion of PROTX2 Technology into the UK and EU; Marks & Spencer to Adopt for Autograph Collections
Canadian Investment Regulatory Organization Trade Resumption - IFA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.